171 related articles for article (PubMed ID: 34872108)
1. Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models.
Wu CH; Wang L; Yang CY; Wen KW; Hinds B; Gill R; McCormick F; Moasser M; Pincus L; Ai WZ
Blood Adv; 2022 Apr; 6(7):2290-2302. PubMed ID: 34872108
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma.
Phillips T; Barr PM; Park SI; Kolibaba K; Caimi PF; Chhabra S; Kingsley EC; Boyd T; Chen R; Carret AS; Gartner EM; Li H; Yu C; Smith DC
Invest New Drugs; 2019 Apr; 37(2):297-306. PubMed ID: 30132271
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.
Pal SK; Forero-Torres A; Thompson JA; Morris JC; Chhabra S; Hoimes CJ; Vogelzang NJ; Boyd T; Bergerot PG; Adashek JJ; Li H; Yu X; Gartner EM; Carret AS; Smith DC
Cancer; 2019 Apr; 125(7):1124-1132. PubMed ID: 30624766
[TBL] [Abstract][Full Text] [Related]
4. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
[TBL] [Abstract][Full Text] [Related]
5. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.
Tannir NM; Forero-Torres A; Ramchandren R; Pal SK; Ansell SM; Infante JR; de Vos S; Hamlin PA; Kim SK; Whiting NC; Gartner EM; Zhao B; Thompson JA
Invest New Drugs; 2014 Dec; 32(6):1246-57. PubMed ID: 25142258
[TBL] [Abstract][Full Text] [Related]
6. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75.
Ryan MC; Kostner H; Gordon KA; Duniho S; Sutherland MK; Yu C; Kim KM; Nesterova A; Anderson M; McEarchern JA; Law CL; Smith LM
Br J Cancer; 2010 Aug; 103(5):676-84. PubMed ID: 20664585
[TBL] [Abstract][Full Text] [Related]
7. CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma.
Nakae R; Matsuzaki S; Serada S; Matsuo K; Shiomi M; Sato K; Nagase Y; Matsuzaki S; Nakagawa S; Hiramatsu K; Okazawa A; Kimura T; Egawa-Takata T; Kobayashi E; Ueda Y; Yoshino K; Naka T; Kimura T
Am J Obstet Gynecol; 2021 Feb; 224(2):197.e1-197.e23. PubMed ID: 32822640
[TBL] [Abstract][Full Text] [Related]
8. Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma.
Leupin N; Zinzani PL; Morschhauser F; Dalle S; Maerevoet M; Michot JM; Ribrag V; Offner F; Beylot-Barry M; Moins-Teisserenc H; Zwaenepoel K; de Winne K; Battistella M; Hultberg A; Gandini D; Moshir M; Jacobs J; Delahaye T; Khan A; Zabrocki P; Silence K; van Rompaey L; Borg C; Motta G; Melle F; Calleri A; Pauwels P; de Haard H; Pileri S; Bagot M
Cancer; 2022 Mar; 128(5):1004-1014. PubMed ID: 34726773
[TBL] [Abstract][Full Text] [Related]
9. CD70 antibody-drug conjugate: A potential novel therapeutic agent for ovarian cancer.
Shiomi M; Matsuzaki S; Serada S; Matsuo K; Mizuta-Odani C; Jitsumori M; Nakae R; Matsuzaki S; Nakagawa S; Hiramatsu K; Miyoshi A; Kobayashi E; Kimura T; Ueda Y; Yoshino K; Naka T; Kimura T
Cancer Sci; 2021 Sep; 112(9):3655-3668. PubMed ID: 34117815
[TBL] [Abstract][Full Text] [Related]
10. SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models.
Mazahreh R; Mason ML; Gosink JJ; Olson DJ; Thurman R; Hale C; Westendorf L; Pires TA; Leiske CI; Carlson M; Nguyen LT; Cochran JH; Okeley NM; Yumul R; Jin S; Stone IJ; Sahetya D; Nesterova A; Allred S; Hensley KM; Hu R; Lawrence R; Lewis TS; Sandall S
Mol Cancer Ther; 2023 Apr; 22(4):421-434. PubMed ID: 36800443
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.
Ryan MC; Palanca-Wessels MC; Schimpf B; Gordon KA; Kostner H; Meyer B; Yu C; Van Epps HA; Benjamin D
Blood; 2017 Nov; 130(18):2018-2026. PubMed ID: 28903943
[TBL] [Abstract][Full Text] [Related]
12. Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB.
Nicolay JP; Müller-Decker K; Schroeder A; Brechmann M; Möbs M; Géraud C; Assaf C; Goerdt S; Krammer PH; Gülow K
Blood; 2016 Aug; 128(6):805-15. PubMed ID: 27268084
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers.
Wang QJ; Yu Z; Hanada KI; Patel K; Kleiner D; Restifo NP; Yang JC
Clin Cancer Res; 2017 May; 23(9):2267-2276. PubMed ID: 27803044
[No Abstract] [Full Text] [Related]
14. Possible therapeutic applicability of galectin-9 in cutaneous T-cell lymphoma.
Nakajima R; Miyagaki T; Kamijo H; Oka T; Shishido-Takahashi N; Suga H; Sugaya M; Sato S
J Dermatol Sci; 2019 Dec; 96(3):134-142. PubMed ID: 31787505
[TBL] [Abstract][Full Text] [Related]
15. CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
Al Sayed MF; Ruckstuhl CA; Hilmenyuk T; Claus C; Bourquin JP; Bornhauser BC; Radpour R; Riether C; Ochsenbein AF
Blood; 2017 Jul; 130(3):297-309. PubMed ID: 28495792
[TBL] [Abstract][Full Text] [Related]
16. Understanding Cell Lines, Patient-Derived Xenograft and Genetically Engineered Mouse Models Used to Study Cutaneous T-Cell Lymphoma.
Gill RPK; Gantchev J; Martínez Villarreal A; Ramchatesingh B; Netchiporouk E; Akilov OE; Ødum N; Gniadecki R; Koralov SB; Litvinov IV
Cells; 2022 Feb; 11(4):. PubMed ID: 35203244
[TBL] [Abstract][Full Text] [Related]
17. LW-213 induces cell apoptosis in human cutaneous T-cell lymphomas by activating PERK-eIF2α-ATF4-CHOP axis.
Yu XX; Zhu MY; Wang JR; Li H; Hu P; Qing YJ; Wang XY; Wang HZ; Wang ZY; Xu JY; Guo QL; Hui H
Acta Pharmacol Sin; 2021 Feb; 42(2):290-300. PubMed ID: 32747719
[TBL] [Abstract][Full Text] [Related]
18. Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.
Jain S; Stroopinsky D; Yin L; Rosenblatt J; Alam M; Bhargava P; Clark RA; Kupper TS; Palmer K; Coll MD; Rajabi H; Pyzer A; Bar-Natan M; Luptakova K; Arnason J; Joyce R; Kufe D; Avigan D
Blood; 2015 Jul; 126(3):354-62. PubMed ID: 26048911
[TBL] [Abstract][Full Text] [Related]
19. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
[TBL] [Abstract][Full Text] [Related]
20. Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.
Li F; Sutherland MK; Yu C; Walter RB; Westendorf L; Valliere-Douglass J; Pan L; Cronkite A; Sussman D; Klussman K; Ulrich M; Anderson ME; Stone IJ; Zeng W; Jonas M; Lewis TS; Goswami M; Wang SA; Senter PD; Law CL; Feldman EJ; Benjamin DR
Mol Cancer Ther; 2018 Feb; 17(2):554-564. PubMed ID: 29142066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
